In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

High prevalence of known and unknown type 2 diabetes mellitus among middle-aged Norwegians: Data from the Akershus cardiac examination (ACE) 1950 study

Session Poster Session 3

Speaker Trygve Berge

Congress : ESC Congress 2018

  • Topic : preventive cardiology
  • Sub-topic : Diabetes and the Heart, Other
  • Session type : Poster Session
  • FP Number : P2530

Authors : T Berge (Gjettum,NO), MN Lyngbakken (Lorenskog,NO), P Smith (Oslo,NO), T Omland (Oslo,NO), K Steine (Oslo,NO), H Rosjo (Oslo,NO), A Tveit (Oslo,NO)

Authors:
T. Berge1 , M.N. Lyngbakken2 , P. Smith3 , T. Omland3 , K. Steine3 , H. Rosjo3 , A. Tveit3 , 1Bærum Hospital, Vestre Viken Hospital Trust, Department of Medical Research - Gjettum - Norway , 2Akershus University Hospital, Division of Medicine - Lorenskog - Norway , 3University of Oslo, Institute of Clinical Medicine - Oslo - Norway ,

On behalf: ACE 1950 study group

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 494

Background: The prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide. More knowledge on the proportion of undiagnosed diabetes in the population may be useful for future prevention strategies. Accordingly; we aimed to report prevalence of known and unknown T2DM, as well as risk factors associated with unknown T2DM, in a middle-aged Norwegian population.

Methods: All women and men born in 1950, residing in Akershus county, Norway, were invited in the Akershus Cardiac Examination (ACE) 1950 study. All participants underwent a clinical examination including fasting blood glucose (FBG) and HbA1c. Known T2DM was defined as self-reported history of T2DM or daily use of antidiabetic drugs, and unknown T2DM was defined as the absence of any of these combined with FBG ≥7.0 mmol/L and HbA1c ≥6.5%. Risk factors associated with unknown T2DM were assessed by multivariate logistic regression.

Results: A total of 3706 among 5827 eligible subjects were included. Mean age was 63.9±0.7 years, 48.8% were women. Known diabetes was reported in 7.2% (9.6% men, 4.6% women; p<0.001). Unknown T2DM was found in 1.3% (1.9% men, 0.7% women; p=0.001), and the total prevalence of diabetes was 8.6% (11.6% in men, 5.4% women; p<0.001). Variables associated with unknown T2DM are presented in Table.

Conclusion: In a contemporary Norwegian population cohort aged 64 years, we identified a considerable proportion of previously unknown T2DM in both sexes, but particularly in men. Elevated BMI, systolic blood pressure, triglycerides, low HDL-cholesterol and a family history of diabetes were associated with unknown T2DM.

Risks associated with unknown T2DM
Univariate OR (95% CI)pMultivariate OR (95% CI)p
Male sex2.90 (1.54–5.47)0.0011.92 (0.95–3.86)0.07
Body mass index1.17 (1.11–1.23)<0.0011.10 (1.04–1.17)<0.01
Systolic blood pressure (per 10 mmHg)1.22 (1.07–1.40)<0.011.18 (1.01–1.38)0.03
Fasting triglycerides1.89 (1.56–2.29)<0.0011.45 (1.16–1.80)0.001
HDL-cholesterol0.08 (0.03–0.19)<0.0010.24 (0.08–0.69)<0.01
History of CVD0.75 (0.23–2.42)0.63
Impaired kidney function-1.14 (0.27–4.74)0.86
Daily smoking0.82 (0.35–1.93)0.65
Higher education0.75 (0.42–1.32)0.32
Sedentary lifestyle1.76 (0.94–3.29)0.081.18 (0.61–2.29)0.63
1 first degree relative with diabetes2.99 (1.62–5.51)<0.0012.62 (1.39–4.95)<0.01
≥2 first degree relatives with diabetes10.54 (4.41–25.17)<0.0019.31 (3.63–23.88)<0.001
All variables with p<0.20 in univariate analyses are included in the multivariate analysis.
Flow chart


Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are